These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28744104)

  • 21. Hepatitis C virus reinfection after liver transplantation: is there a role for direct antiviral agents?
    Dall'Agata M; Gramenzi A; Biselli M; Bernardi M
    World J Gastroenterol; 2014 Jul; 20(28):9253-60. PubMed ID: 25071318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study.
    Ferrarese A; Germani G; Gambato M; Russo FP; Senzolo M; Zanetto A; Shalaby S; Cillo U; Zanus G; Angeli P; Burra P
    World J Gastroenterol; 2018 Oct; 24(38):4403-4411. PubMed ID: 30344424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
    Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No need to discontinue hepatitis C virus therapy at the time of liver transplantation.
    Skoglund C; Lagging M; Castedal M
    PLoS One; 2019; 14(2):e0211437. PubMed ID: 30794555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
    Lim KB; Sima HR; Fiel MI; Khaitova V; Doucette JT; Chernyiak M; Ahmad J; Bach N; Chang C; Grewal P; Kim-Schluger L; Liu L; Odin J; Perumalswami P; Florman SS; Schiano TD
    World J Gastroenterol; 2015 May; 21(20):6236-45. PubMed ID: 26034358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y
    J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience.
    Araujo A; Valenzuela-Granados V; Lopes AB; Michalczuk MT; Mantovani A; Alvares-da-Silva MR
    Ann Hepatol; 2019; 18(3):450-455. PubMed ID: 31028014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
    Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
    Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ;
    Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
    Kumada H; Watanabe T; Suzuki F; Ikeda K; Sato K; Toyoda H; Atsukawa M; Ido A; Takaki A; Enomoto N; Kato K; Alves K; Burroughs M; Redman R; Pugatch D; Pilot-Matias TJ; Krishnan P; Oberoi RK; Xie W; Chayama K
    J Gastroenterol; 2018 Apr; 53(4):566-575. PubMed ID: 29052790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.
    D'Ambrosio R; Pasulo L; Puoti M; Vinci M; Schiavini M; Lazzaroni S; Soria A; Gatti F; Menzaghi B; Aghemo A; Capelli F; Rumi MG; Morini L; Giorgini A; Pigozzi MG; Rossini A; Maggiolo F; Pan A; Memoli M; Spinelli O; Del Poggio P; Saladino V; Spinetti A; De Bona A; Capretti A; Uberti-Foppa C; Bonfanti P; Terreni N; Menozzi F; Colombo AE; Giglio O; Centenaro R; Borghi M; Baiguera C; Picciotto V; Landonio S; Gori A; Magnani C; Noventa F; Paolucci S; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Mar; 70(3):379-387. PubMed ID: 30472321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders.
    Dybowska D; Zarębska-Michaluk D; Rzymski P; Berak H; Lorenc B; Sitko M; Dybowski M; Mazur W; Tudrujek-Zdunek M; Janocha-Litwin J; Janczewska E; Klapaczyński J; Parfieniuk-Kowerda A; Piekarska A; Sobala-Szczygieł B; Dobrowolska K; Pawłowska M; Flisiak R
    World J Gastroenterol; 2023 Jul; 29(25):4085-4098. PubMed ID: 37476581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    Lu M; Wu KH; Li J; Moorman AC; Spradling PR; Teshale EH; Boscarino JA; Daida YG; Schmidt MA; Rupp LB; Zhang T; Trudeau S; Gordon SC
    J Viral Hepat; 2019 Oct; 26(10):1210-1217. PubMed ID: 31197910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
    Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
    J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
    Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.